Excimerlight has initiated its North American expansion with a filter-free 222nm far-UVC technology platform designed to continuously disinfect indoor environments without requiring filtration systems. The Japanese company’s market entry positions it to compete in the growing ultraviolet disinfection sector, which industry analysts project will reach $12.5 billion globally by 2028.
The technology operates at a precise 222-nanometer wavelength that research from the Centers for Disease Control and Prevention indicates can inactivate pathogens including viruses and bacteria while remaining safe for occupied spaces. Unlike conventional 254nm UV-C systems that pose health risks to human exposure, far-UVC light at 222nm cannot penetrate the outer layer of human skin or the tear layer of eyes, according to peer-reviewed studies published in radiation research journals.
Excimerlight’s filter-free design eliminates maintenance requirements associated with traditional far-UVC systems that rely on optical filters to isolate the 222nm wavelength. These filters typically degrade over time, requiring replacement every 1,000 to 3,000 hours of operation. The company’s proprietary excimer lamp technology generates the target wavelength directly without requiring filtration, reducing total cost of ownership by approximately 40 percent over a five-year operational period compared to filtered alternatives.
The North American indoor air quality market has experienced substantial growth since 2020, with commercial building owners investing heavily in pathogen reduction technologies. Market research indicates that 68 percent of facility managers now prioritize continuous disinfection capabilities when upgrading HVAC and air quality systems. This demand extends across healthcare facilities, educational institutions, hospitality venues, and corporate office environments where maintaining pathogen-free conditions has become an operational priority.
Healthcare-associated infections affect one in 31 hospital patients on any given day according to the World Health Organization, creating substantial economic burden estimated at $28 billion annually in direct medical costs. Far-UVC technology offers continuous disinfection capabilities that complement existing infection control protocols without requiring room evacuation or operational disruptions common with traditional UV-C systems.
Excimerlight’s technology platform includes multiple form factors ranging from ceiling-mounted fixtures suitable for large commercial spaces to portable units designed for smaller environments. The systems integrate with building management systems through standard protocols, enabling automated operation based on occupancy patterns and environmental conditions. Real-time monitoring capabilities provide facility managers with data on operational hours, pathogen reduction rates, and maintenance scheduling.
The company’s entry follows increasing regulatory clarity around far-UVC technology deployment. The American Conference of Governmental Industrial Hygienists established threshold limit values for 222nm exposure in 2022, providing standardized safety guidelines that facilitate wider commercial adoption. These standards specify maximum daily exposure levels of 160 millijoules per square centimeter over an eight-hour period, well above typical operational parameters for properly installed far-UVC systems.
Independent laboratory testing demonstrates that Excimerlight’s platform achieves 99.9 percent pathogen reduction rates for common airborne and surface contaminants within 15 minutes of continuous operation in standard room configurations. Testing protocols followed ISO 15714 standards for UV-C devices and included evaluation against SARS-CoV-2, influenza A, and methicillin-resistant Staphylococcus aureus among other pathogens.
The North American expansion includes establishing distribution partnerships with commercial building equipment suppliers and healthcare technology providers. Excimerlight plans to open technical support centers in major metropolitan regions to provide installation guidance, training programs for facility management teams, and ongoing service support. The company projects initial market penetration across 500 commercial facilities within the first 18 months of operations, targeting healthcare, education, and corporate office segments as primary adoption channels.